HOT NEWS
Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product sup... » Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides ...
43 research talents awarded scholarships to help secure Denmark's future » 43 of Denmark's most talented students in the biotechnological and pharmaceutical sciences will toda...
Novartis drug Signifor® recommended by CHMP for EU approval » The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ado...
Genzyme Announces European Approval of Framingham Manufacturing Plant » Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Me...
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe » AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provi...
MyAsthma App - a New Dimension in Asthma Control » GlaxoSmithKline (GSK) has announced the launch of MyAsthma, the UK's first, free personalised health...
Shire's Venvanse® (lisdexamfetamine dimesylate) Marketing Application accepted ... » Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced...
Bayer's Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Sec... » Bayer HealthCare has submitted an application for marketing authorization to the European Medicines ...
Avastin receives EU approval for the treatment of women with newly diagnosed, ad... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Avastin (beva...
First-of-its-Kind Endovascular Trial of the Investigational Esprit(TM) Therapy » Abbott (NYSE: ABT) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in...
Newsfeeds
Breaking World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements.

  • Websites advertising cholesterol-lowering drugs of poor quality
    A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that internet sites selling prescription statins directly to consumers are widespread, and that most websites advertising statins for sale to the general public contain very poor levels of information relevant to safe use of the medicine and side effects.

  • AstraZeneca fourth quarter and full year results 2011
    AstraZenecaAstraZeneca's revenue in the fourth quarter was unchanged at CER and on an actual basis as exchange rate movements were neutral to reported revenue. Adjusted for the disposal of Astra Tech, revenue growth was 2 percent.

  • Protein structures give disease clues
    Using some of the most powerful nuclear magnetic resonance equipment available, researchers at the University of California, Davis, are making discoveries about the shape and structure of biological molecules - potentially leading to new ways to treat or prevent diseases such as breast cancer and Alzheimer's disease.

  • Pfizer reports fourth-quarter and full-year 2011 results
    PfizerPfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2011. Fourth-quarter 2011 revenues were $16.7 billion, a decrease of 4% compared with $17.4 billion in the year-ago quarter, which reflects an operational decline of $765 million, or 5%, and the favorable impact of foreign exchange of $157 million, or 1%.

  • Novartis extends commitment to help achieve final elimination of leprosy
    NovartisNovartis will continue its work with the World Health Organization (WHO) toward a world free of leprosy by extending its drug donation of multidrug therapy (MDT) medicines to treat leprosy through the year 2020.

  • Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion
    AmgenAmgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010. For the full year 2011, total revenue increased 4 percent to $15,582 million from $15,053 million in 2010.

  • Alzheimer's Challenge 2012: seeking new tools to help improve Alzheimer's care
    PfizerPfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer's Immunotherapy Program (AIP), Janssen Alzheimer Immunotherapy, and the Geoffrey Beene Gives Back® Alzheimer's Initiative introduced the Alzheimer's Challenge 2012 at the Care Innovations Summit in Washington, D.C.

  • Bristol-Myers Squibb delivers solid fourth quarter capping a year highlighted by new product approvals
    Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) announced solid financial results for the fourth quarter of 2011. This concludes a year in which the Company received important new product approvals for YERVOY® and NULOJIX® in both the U.S. and Europe, and ELIQUIS® in Europe for the prevention of venous thromboembolic events.

  • Amgen to Acquire Micromet
    AmgenAmgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash.

  • Novartis delivers strong underlying financial performance in 2011
    NovartisNovartis' net sales rose 4% (+5% cc) to USD 14.8 billion in the fourth quarter. The strengthening of the US dollar against most major currencies negatively impacted sales by 1 percentage point.

Bookmark and Share